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Lung transplantation for COPD –
evidence-based?
Samir Lahzami, John-David Aubert
Service de Pneumologie et Centre de Transplantation, CHUV et Université de Lausanne, Switzerland
Lung transplantation has now been per-
formed for more than 30 years in patients with
end-stage chronic obstructive pulmonary disease
(COPD). This disease is the major indication for
lung transplantation, involving more than one
third of the procedures worldwide. Although lung
transplantation in COPD patients has clearly
shown a positive impact on lung function, exer-
cise capacity and quality of life, the survival bene-
fit remains difficult to ascertain. Several method-
ological difficulties, particularly the absence of
classical randomised studies, make the analysis es-
pecially challenging. There is however indirect
but convincing evidence that lung transplantation
can, when appropriate selection criteria are ap-
plied, provide not only an active post-transplant
lifestyle but also a survival benefit for patients
with COPD.
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Summary
Chronic obstructive pulmonary disease
(COPD) is a major health problem in developed
countries and a growing concern in low income
nations as well. Epidemiological data show that
the prevalence of COPD is increasing worldwide
and it is expected that the number of patients with
severe disease and the overall morbidity and mor-
tality will increase in the coming years [1]. The
global management of COPD is now well defined
through international initiatives, and there is a
broad consensus on therapeutic measures that are
useful in this condition [2]. Treatment of COPD
includes both pharmacological and non-pharma-
cological measures, with a stepwise approach de-
pending on the severity of the disease. Although
morbidity can usually be effectively alleviated,
only a few treatments have had a real impact on
mortality. Among these, the most cost-effective
measure by far is the eradication of the exogenous
risk factors, among which active or passive inhala-
tion of cigarette smoke accounts for more than
90% of all cases. Pivotal cohort studies have
demonstrated without any doubt the influence of
cigarette smoke on airflow limitation and the
benefit from quitting smoking, whatever the ex-
tent of the disease [3, 4]. Another cornerstone of
care in COPD, although limited to a small subset
of patients with severe disease, is the administra-
tion of long term oxygen therapy [5, 6]. Along
with smoking cessation, it is the only medical
treatment with a definite survival benefit in
COPD.
In the late 90s great hopes were placed in the
antiinflammatory properties of inhaled steroids,
but ten years later there is still ongoing debate as
to the real impact of this therapeutic class on
mortality in COPD [7, 8]. If medical treatments
other than smoking cessation and oxygen therapy
have failed to demonstrate a survival benefit, their
utility in the daily management of COPD is well
established and consists in symptomatic relief, a
decreased rate of exacerbations and improved
exercise tolerance. This category of treatment
includes bronchodilators, pulmonary rehabilita-
tion and chronic non-invasive home ventilation
[2].
Evidence-based medical management of COPD
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Surgical options have also been evaluated for
patients with advanced emphysema. The North
American National Emphysema Treatment Trial
group (NETT) has demonstrated, through a
carefully randomised study, a significant survival
advantage after lung volume reduction surgery
for patients with severe emphysema with both
upper-lobe predominance and low baseline exer-
cise capacity [9]. In an extension study, the au-
thors have recently shown that this benefit ex-
tends beyond three years [10]. It must be empha-
sized that the clinical characteristics of the pa-
tients who will benefit from this type of surgery
are relatively narrow, and therefore, unfortu-
nately, a majority of patients with severe COPD
will never meet the stringent criteria established
by the NETT study.
Surgical treatment in COPD
Lung transplantation
Lung transplantation in patients with emphy-
sema was first reported in the 70s and has been
more widely practised since the late 80s. In the
last decade more than 6500 lung transplants have
been performed in patients with COPD (exclud-
ing α1-antitrypsin deficiency), which represents
some 37% of all indications [11]. According to
data from the International Society for Heart and
Lung Transplantation Registry (ISHLT), survival
achieved in the last ten years is now 81.5% for the
first year and 64% after three years [11]. Table 1
gives the survival rates for selected published se-
ries from national and international cohorts. In
comparison to other indications, recipients with
COPD have the best first-year survival but the
poorest survival after 10 years, with only 20% of
recipients alive. This attrition probably reflects
the older age of patients with COPD compared to
patients with other diseases (e.g. cystic fibrosis)
and possibly the toll of comorbidities such as a
damaged cardiovascular system in former smok-
ers. Whereas heart-lung transplantation is nowa-
days no longer performed in COPD except for
some specific cases, single lung transplantation re-
mains an option provided that no chronic suppu-
rative airway disease remains in the native lung. In
very recent years single lung transplantation has
been performed in about 45% of transplant recip-
ients with COPD, whereas it was the operation of
choice in the early 90s. Early post-transplant sur-
vival appears to be similar in single versus double
lung transplantation. However, in the largest
studied cohort (9883 patients), the median sur-
vival after single lung transplantation (4.6 years)
was significantly shorter than after double lung
transplanation (6.4 years) [12]. According to these
data single lung transplantation is considered an
option for older recipients aged 60 years or over
or for patients with additional comorbidities, no-
tably of the cardiovascular system, that increase
the perioperative risk [13].
Criteria for lung transplantation
Earlier criteria for lung transplantation in
COPD were the presence of an FEV1 <25% of
predicted value, a PaCO
2
≥55 mm Hg (7.3 kPa),
or the diagnosis of concomitant pulmonary hyper-
tension with progressive clinical deterioration [14,
15]. These criteria have been used for many years
as guidelines for the selection of COPD lung
transplant candidates. In 2004, Celli and col-
leagues published, from a large multicentric co-
hort of COPD patients, a composite of four pa-
rameters showing a strong association with sur-
vival in COPD: Body-mass index (BMI), airflow
Obstruction, Dyspnoea and Exercise capacity
[16]. These parameters were used to design the
BODE index, a validated scoring system which
proved to be a better predictor of survival than the
spirometric staging system developed by the
American Thoracic Society [17]. The BODE
index assigns a score for disease severity on a scale
of 0 to 10, with the higher score indicating a more
severe disease and predicting a poorer outcome
for the next four years (table 2).
The BODE index was recently adopted by the
ISHLT expert panel. The 2006 updated interna-
Registry (ref) Period N 1-year 3-year
survival survival
ISHLT [11] 1994–2004 7113 81 64
ISHLT [11] 2003–2007 1712 85.8 69.1
UNOS/USA [31] 1997–2004 1209 86.6 66.0
Swiss registry [32] 1992–2002 79 80 75
Australia [33] 1989–2003 112 86 NA
St Louis [34] 1988–2000 220 88.8 76.5
ISHLT = International Society for Heart and Lung
Transplantation
UNOS = United Network for Organ Sharing
Table 1
Survival after lung
transplantation for
COPD from different
registries.
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tional guidelines for the selection of lung trans-
plant candidates [18] added a BODE ≥5 for refer-
ral to a transplant centre and a score ≥7 for pa-
tient listing. However, these guidelines have not
yet been validated by retrospective or prospective
cohort studies. The expert recommendations are
given in table 3.
Parameters/points 0 1 2 3
BMI kg/m
2
>21 ≤21
FEV
1
% predicted ≥65 50–64 36–49 <35
MMRC dyspnea scale 0–1 2 3 4
6-minute walk test (m) ≥350 250–349 150–249 ≤149
Table 2
Clinical parameters
of the BODE index
[16].
Published studies on the survival benefit after transplantation in COPD
Several groups have addressed the question of
survival benefit after lung transplantation for
COPD.All the studies to date have compared sur-
vival after transplantation to survival of patients
on the waiting list (table 4). Whereas two papers
found no survival benefit for COPD patients [19,
20], three have established some survival advan-
tage at least for selected subgroups [21–23]. It
should be noted that all the studies but one have
included patients with a-1 antitrypsin deficiency,
and that the time frame under study is rather
large, dating back to the late 80s, a time when lung
transplantation was still in its infancy. Accord-
ingly, most studies reported a one-year survival
significantly inferior to more recent data from na-
tional and international registries (table 1). More-
over, it is likely that patients were listed somewhat
prematurely in the early years, increasing the dis-
advantage of transplantation compared to survival
on the waiting list. The recently published analy-
sis by Thabut and colleagues is by far the largest
and most sophisticated study on the topic [22].
Founded on the UNOS registry, these authors
have developed a model based on individual risk
factors to predict survival with and without trans-
plantation for patients with COPD. Among the
most discriminating parameters was the need for
oxygen, the need for mechanical ventilation, the
6-minute walk distance, the presence of pul-
monary hypertension and FEV
1
. Here again the
control group was the cohort of patients on the
waiting list. According to their statistical analysis,
Thabut et al. found a survival benefit in about
50% of recipients after lung transplantation. Im-
portantly, this analysis was performed under the
old allocation policy of the UNOS organisation
based essentially on waiting time, whereas the new
lung allocation score prioritises recipients accord-
ing to disease severity in order to increase trans-
plant benefit [24]. As the authors and their review-
ers acknowledged, it would be premature to use
their equations on a clinical basis until externally
validated and tested with other lung allocation
systems [25].
The ISHLT registry data show that double
lung recipients have a significantly better long
term survival than single lung recipients [11].
However, this advantage seems to disappear for
patients aged 60 or over [12]. Hence the proce-
dure of choice for this category of recipients is
still debated.
Patients with a BODE index of 7 to 10 or at least 1
of the following:
History of hospitalisation for exacerbation associated
with acute hypercapnia (PCO
2
>50 mm Hg/6.7 kPa)
Pulmonary hypertension or cor pulmonale, or both, despite
oxygen therapy.
FEV
1
of <20% predicted and either DLCO of <20% predicted
or homogeneous distribution of emphysema.
Table 3
Criteria for listing
lung recipient candi-
dates among COPD
patients [18].
Ref Patients Period α1-AT deficiency Follow-up 1 year survival % Main result
included analysed excluded (years)
[20] 843 1992–1994 yes 2 82 No benefit
[23] 395 1990–1996 no 2 67 Benefit after 260 d
[21] 122 1984–1999 no 1 73 Benefit after 1 year
[19] 86 1990–2003 no 4 74 No benefit
[22] 5873 1987–2004 no 5 (median) 86.6* Benefit in ~50%
* According to the UNOS registry 1997–2004 from which the data were collected
α1-AT = alpha 1-antitrypsin
Table 4
Published studies on
the survival benefit
after lung transplan-
tation for COPD.
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Organ transplantation cannot be evaluated in
the same way as other conventional therapy. For
obvious ethical reasons it will never be possible to
conduct a true randomised study involving poten-
tial lung recipient candidates. Hence, according
to the established rules of evidence-based medi-
cine, lung transplantation will never receive the
“A” label granted only after rigorously designed
randomised and blinded studies. Another
methodological problem lies in the definition of
the true medical decision in the process of organ
transplantation: the major medical procedure is to
list or not to list a patient for transplantation.The
subsequent decision to transplant a patient on the
waiting list will depend on the local allocation
rules and potential contraindications either for
the donor or the recipient. The time on the wait-
ing list will therefore depend on the specific
organ allocation rules, which differ from country
to country. In some organisations (e.g. UNOS for
the USA) disease severity is now a criterion for al-
location, whereas in other countries (e.g. Switzer-
land) this is not the case and the waiting time is
the main determinant except for some specific
high urgency criteria. In other words, the survival
benefit of listing should be distinguished from the
benefit of transplantation [25]. Moreover, it is
likely that patients on the waiting list do not re-
ceive the same type of care as patients not consid-
ered for or denied lung transplantation. For all
these reasons, comparisons of survival for patients
after lung transplantation and those on the wait-
ing list are potentially biased, as are comparisons
of programmes with different allocation systems.
A methodologically correct evaluation would
be, as applied by the investigators of the NETT
study for lung volume reduction [9], to randomise
eligible patients for lung transplantation to either
a waiting list or to best standard care, and com-
pare mortality in the two groups including deaths
on the waiting list. As such a study will probably
never be performed, another approach could be
to compare actual survival after lung transplanta-
tion with the predicted survival determined by
markers of disease severity such as the BODE
index [16]. This latter approach would be largely
free of the bias mentioned above. However, the
discriminative power of such survival equations
should be robust, and caution is needed when ex-
tending them to populations from other geo-
graphical areas or other time periods.
Methodological problems in assessing the survival benefit of lung
transplantation
Beyond survival benefit
While demonstrating a survival advantage re-
mains a challenge in lung recipients with COPD,
these patients clearly benefit from enhanced lung
function, better exercise tolerance [26, 27] and,
most importantly, a better quality of life [28].
These benefits are especially crucial for lung
transplant candidates with COPD. It is of interest
to note that the benefit in quality of life seems to
persist even when there is some decrease in lung
function, as found in the bronchiolitis obliterans
syndrome [29]. With a mean age of 56 years at
transplant (11), many of these patients would
readily exchange years of life crippled with severe
disease for the same or even a smaller number of
years with a better quality of life [25]. However,
the dramatic shortage of organs available for
transplantation faces the transplant team with an
ethical dilemma in weighing patients’ needs and
equity in the allocation of scarce resources: trans-
planting patients with no predictable survival ad-
vantage after the procedure may well jeopardise
the survival of others on the waiting list who
would definitively survive longer if transplanted.
The new Lung Allocation Score system, intro-
duced in May 2005 in the USA, was established to
address this question by estimating the respective
transplant benefit of all listed patients [24, 30].
How this new system will alter disease distribu-
tion in lung transplantation programmes and the
selection criteria for candidates with COPD in
this country warrants prospective long term stud-
ies.
Conclusion
Lung transplantation is a therapeutic option in
carefully selected patients with COPD, provided
they fulfil established inclusion and exclusion crite-
ria.When these criteria are met, there is strong ev-
idence that amajority of these recipients will derive
a survival advantage from the procedure, together
with an improvement in lung function, exercise ca-
pacity and quality of life. Better predictors of mor-
tality in COPD are likely to help transplant teams
worldwide to select candidates and refine the list-
ing criteria.These tools will be crucial in achieving
a fair allocation of what remains a limited resource.
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